Exosome RNA Exosome RNA Research & Industry News
Avalon GloboCare announced Thursday that CEO David Jin will unveil the launch of the company’s new commercialization plan for its exosome...
Read More »Avalon GloboCare CEO David Jin to unveil exosome commercialization plan at China confab
Avalon GloboCare to host the 3rd Annual International Scientific Forum on Exosome Research and Application (ISFERA)
Avalon GloboCare a leading global developer of innovative and transformative cell-based technologies and therapeutics, announced today that it will co-organize the 3rd Annual International Scientific Forum on Exosome Research and Application (ISFERA)...
Read More »Avalon GloboCare Teams Up with Weill Cornell Medicine to Co-develop Standardization of cGMP-Grade Exosome Isolation and Application of Tissue-Specific Exosomes
Avalon GloboCare Corp, a leading global developer of cell-based technologies and therapeutics, announced today that Weill Cornell Medicine has selected its subsidiary Genexosome Technologies’ proprietary...
Read More »Avalon GloboCare Forms Joint Laboratory with Top-Ranked Hospital in Shanghai for Regenerative Exosomics
Avalon GloboCare Corp. a global developer of cell-based technologies, announced today that the Company's subsidiary, GenExosome Technologies Inc., has formed a joint laboratory for regenerative exosomics with the Shanghai Ninth People's Hospital (SNPH), a top-ranked medical institute...
Read More »Avalon GloboCare subsidiary GenExosome expands operations into the US
Launches US headquarters for marketing and distribution of proprietary Exosome Isolation System Announces plans to introduce proprietary diagnostic and therapeutic products leveraging exosome technology Avalon GloboCare Corp a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary, GenExosome ...
Read More »Avalon GloboCare Acquires Leading Beijing Exosome Technology Company
Avalon GloboCare Corp. a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary GenExosome Technologies Inc. (GenExosome) acquired 100% of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. Concurrently, GenExosome entered into and ...
Read More »